General Announcement::Glenmark Presents New Data on Ryaltris an Investigational Product

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
06-Mar-2018 11:36:21
Status
New
Announcement Sub Title
Glenmark Presents New Data on Ryaltris an Investigational Product
Announcement Reference
SG180306OTHRP661
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
06/03/2018 09:01:00
Description (Please provide a detailed description of the event in the box below)
Glenmark Pharmaceuticals Presents New Data on Ryaltris an Investigational Product for the Treatment of Seasonal Allergic Rhinitis at the AAAAI/WAO Joint Congress

Attachments

Final_PR.pdf
Total size =796K